No Data
No Data
Barclays Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $30
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Here's Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference